Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PCSK9 List Price Discounts Of 67% To 85% Suggested By ICER Analysis

Executive Summary

Methods and conclusions for group’s report on the value and optimal pricing for Repatha and Praluent draw criticism from drug industry stakeholders, some policy experts. Approach includes cost-effectiveness review, novel US budget impact analysis.

You may also be interested in...

Value Vs. Values: ICER’s Review Of Opioid Abuse-Deterrent Formulations

The Institute for Clinical & Economic Review is setting an appropriately broad scope in its review of the abuse-deterrent opioid class. But the project opens up a much larger question of how broadly to define value – and how to weigh non-economic values – in cost-effectiveness reviews.

PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press

Analysis published in the Journal of the American Medical Association is the latest to argue that PCSK9 inhibitors are not cost-effective.

ICER Eyes QALY Ratios, Budget Impacts In Methods Review

Institute for Clinical and Economic Review plans to unveil an updated drug value framework in early 2017.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts